Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities.

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Abstract Text:

Impaired glucose tolerance and non-insulin-dependent diabetes (NIDDM) are the pathologic consequence of two co-incident and interacting conditions, namely insulin resistance and relative insulin deficiency. Recognised by the World Health Authority as a global health problem there are at 1995 estimates at least 110 million diagnosed diabetics world wide with at least the same number undiagnosed. Diabetes is the 4th leading cause of death in developed countries and its management exerts a vast economic and social burden. Insulin resistance is established as the characteristic pathologic feature of patients with glucose intolerance and NIDDM describing a state in which insulin stimulated glucose uptake and utilisation in liver, skeletal muscle and adipose tissue is impaired and coupled to impaired suppression of hepatic glucose output. Although the biochemical mechanisms underpinning both defects are becoming better understood, the genetic and molecular causes remain elusive; and whether insulin resistance or relative insulin deficiency represents the primary defect in patients with NIDDM is the matter of some debate. In this article we review the biochemical and molecular nature of the defects in insulin sensitivity and glucose uptake, and discuss some of the potential causative mechanisms. The genetic and environmental basis of insulin resistance is reviewed and presented, and potential therapeutic targets including thiazolidinediones are discussed.

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Publishing Authors By Initials

For similar digestive system: pancreas research abstracts see: digestive system: pancreas research

PUBMED ID PMID:

MEDLINE DATE:

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Journal Published:

PUBLICATION TYPE: Review

Journal: Progress in drug research. Fortschritte der Arznei

VOLUME: 51

Page Numbers: 33-94

Journal Abbreviation:

ISSN: 0071-786X

DAY: 25

MONTH: 02

YEAR: 1998

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Information

Number of References: 370

LANGUAGE: eng

NlmUniqueID: 1304021

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Keywords Mesh Terms:

KEYWORDS: Pancreas

MESH TERMS: metabolism

Chemical & Substance for Abstract: Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities. Information

Substance Name: Glucose

Registry Number: 50-99-7

Grant and Affiliation Information for Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities.

AFFILIATION: SmithKline Beecham Pharmaceuticals, New Frontiers Science Park (N), Harlow, Essex, UK.

Country: SWITZERLAND

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Prog Drug Res

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities Related Publications

• Activating mutation in a mucolipin transient receptor potential channel leads to melanocyte loss in varitint-waddler mice.
• All four CatSper ion channel proteins are required for male fertility and sperm cell hyperactivated motility.
• Bisandrographolide from Andrographis paniculata activates TRPV4 channels.
• Calcium signaling.
• Citral sensing by TRANSient receptor potential channels in dorsal root ganglion neurons.
• Derivatives of 2 :4 :6-trinitrotoluene; the nitration of polynitrostilbenes, 2-(2 :4 :6-trinitrophenyl) ethyl alkyl (aryl) sulphides.
• Differential regulation of adipocytokine mRNAs by rosiglitazone in db/db mice.
• Gag regulates association of human immunodeficiency virus type 1 envelope with detergent-resistant membranes.
• HIV and chemokines: ligands sharing cell-surface receptors.
• Hallux valgus; predisposing anatomical causes.
• Heterologous array analysis in pinaceae: hybridization of pinus taeda cDNA arrays with cDNA from needles and embryogenic cultures of p. Taeda, p. Sylvestris or picea abies.
• Human immunodeficiency viruses: propagation, quantification, and storage.
• Insulin resistance, impaired glucose tolerance and non-insulin-dependent diabetes, pathologic mechanisms and treatment: current status and therapeutic possibilities.
• Intracellular calcium. Replenishing the stores.
• Ion channels that control fertility in mammalian spermatozoa.
• KSper, a pH-sensitive K+ current that controls sperm membrane potential.
• Lack of alternative coreceptor use by pediatric HIV-1 R5 isolates for infection of primary cord or adult peripheral blood mononuclear cells.
• Lignin biosynthesis in transgenic Norway spruce plants harboring an antisense construct for cinnamoyl CoA reductase (CCR).
• Natural Resistance of Human Immunodeficiency Virus Type 1 to the CD4bs Antibody b12 Conferred by a Glycan and an Arginine Residue Close to the CD4 Binding Loop.
• RENAL HYPERTENSION AND POLYCYTHAEMIA.
• Some derivatives of thionaphthen.
• Spruce embryogenesis.
• TRPM7 facilitates cholinergic vesicle fusion with the plasma membrane.
• The promise of CCR5 antagonists as new therapies for HIV-1.
• Variation in HIV-1 R5 macrophage-tropism correlates with sensitivity to reagents that block envelope: CD4 interactions but not with sensitivity to other entry inhibitors.
• Variation of macrophage tropism among HIV-1 R5 envelopes in brain and other tissues.